UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 5, 2025

AMICUS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-33497		71-0869350
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

47 Hulfish Street, Princeton, New Jersey 08542

(Address of Principal Executive Offices, and Zip Code)

609-662-2000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock Par Value $0.01		FOLD		NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07 - Submission of Matters to a Vote of Security Holders.

At the 2025 Annual Meeting of Stockholders of the Company, held on June 5, 2025, the Company’s stockholders elected Michael A. Kelly, Margaret G. McGlynn, Michael G. Raab and Glenn P. Sblendorio as Class III directors to serve a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their respective successors have been elected. In addition, the stockholders (i) approved the 2025 Equity Incentive Plan, (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, and (iii) approved, on an advisory basis, the compensation paid to the Company’s named executive officers. The final voting results on these matters were as follows:

Election of Directors.

Nominee	Votes For		Votes Withheld		Broker Non-Votes
Michael A. Kelly		256,542,874		5,972,321		20,343,283
Margaret G. McGlynn		253,119,576		9,395,619		20,343,283
Michael G. Raab		159,986,932		102,528,263		20,343,283
Glenn P. Sblendorio		255,741,822		6,773,373		20,343,283

Approval of the 2025 Equity Incentive Plan.

Votes For				Votes Against				Votes Abstain				Broker Non-Votes
	253,118,014				8,908,436				488,745				20,343,283

Ratification of Ernst & Young LLC as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025.

Votes For				Votes Against				Votes Abstain				Broker Non-Votes
	277,786,618				5,006,701				65,159				-

Approval, on an advisory basis, of the Company's executive compensation.

Votes For				Votes Against				Votes Abstain				Broker Non-Votes
	255,789,585				6,169,769				555,841				20,343,283

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signature Page

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AMICUS THERAPEUTICS, INC.
Date: June 5, 2025	By:	/s/ Ellen S. Rosenberg
	Name:	Ellen S. Rosenberg
	Title:	Chief Legal Officer and Corporate Secretary

AMICUS THERAPEUTICS, INC. 8-K